S'abonner

Research Progress on the Regulatory Role of Different Cell Death Pathways in Metabolic-dysfunction-associated Steatotic Liver Disease - 31/03/25

Doi : 10.1016/j.clinre.2025.102578 
Congyue Zhang a, , # , Mengjiao Sun a, #, Yuanjian Ding b, #, Xiwei Yuan a, Jingyi Lu c, Yuemin Nan a
a Department of Integrated Traditional Chinese and Western Medicine Hepatology, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China 
b Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, Japan 
c Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China 

Correspondence to: Congyue Zhang, Hebei Medical University Third Hospital.Hebei Medical University Third Hospital
Sous presse. Manuscrit accepté. Disponible en ligne depuis le Monday 31 March 2025
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Highlights

This review explores the mechanisms of various cell death pathways—apoptosis, pyroptosis, autophagy, ferroptosis, and cuproptosis—and their roles in the pathogenesis of metabolic-dysfunction-associated fatty liver disease (MAFLD). It is the first comprehensive review to focus on the interplay of these cell death mechanisms in MAFLD.
Diversity and Interaction of Cell Death Pathways: The review emphasizes that during the development of MAFLD, multiple cell death pathways are not isolated but are interconnected, influencing the pathological progression synergistically. The article discusses how different forms of cell death, including apoptosis, pyroptosis, autophagy, ferroptosis, and cuproptosis, contribute to liver pathology through distinct molecular mechanisms, and further examines their interactions and collaborative effects.
Role of Apoptosis and Pyroptosis in MAFLD: Apoptosis, a classical form of programmed cell death, plays a critical role in the progression of MAFLD. This review details how hepatocyte apoptosis exacerbates inflammation, cell damage, and fibrosis during fatty liver development, focusing on mitochondrial dysfunction and oxidative stress as key drivers of apoptosis. The review also highlights the significant role of pyroptosis, particularly in liver inflammation. A pyroptosis is a form of programmed cell death induced by inflammasome activation, and studies have shown that inflammasomes such as AIM2 and NLRP3 are activated in MAFLD, leading to hepatocyte pyroptosis and intensifying liver inflammation and damage.
4. Ferroptosis and Cuproptosis in NAFLD: The review further delves into the emerging roles of ferroptosis and cuproptosis as novel cell death pathways in MAFLD. Ferroptosis, characterized by iron-induced lipid peroxidation, is closely linked to oxidative stress and inflammation in MAFLD. Cuproptosis, a copper-dependent form of cell death, although still in the early stages of research, suggests that copper metabolism abnormalities may significantly affect liver function and contribute to cell death.
5. Potential Therapeutic Targets and Strategies: The review also discusses therapeutic strategies targeting different cell death pathways, particularly focusing on modulating cell death mechanisms to alleviate liver injury in MAFLD. For instance, inhibiting pyroptosis, ferroptosis, or enhancing autophagic function may represent key directions in mitigating the progression of MAFLD, thus offering new perspectives for its treatment.
Conclusion: In summary, this review highlights the critical role of cell death mechanisms in the pathogenesis of MAFLD. By providing a multidimensional perspective on the different forms of cell death, this review not only enhances our understanding of the pathology of MAFLD but also offers new insights into potential therapeutic strategies. Targeting specific cell death pathways to mitigate liver damage and slow the progression of MAFLD holds significant promise for future treatment options.

Le texte complet de cet article est disponible en PDF.

Abstract

Metabolic dysfunction associated steatotic liver disease (MASLD) is one of the most common chronic liver diseases that pose a significant threat to human health. An essential process in developing various diseases, including MASLD, is programmed cell death, a regulated and controlled mechanism that eliminates damaged or unnecessary cells. It is a ubiquitous process during organismal development and represents an active, orderly form of cell death. Significant progress has been made in studying programmed cell death in the context of MASLD. This review systematically summarizes various forms of cell death, including apoptosis, Pyroptosis, autophagy, ferroptosis, and cuproptosis, along with their regulatory mechanisms in MASLD. It has been observed that there are interactions between different forms of cell death. As MASLD progresses through inflammation, fibrosis, and cirrhosis stages, multiple forms of cell death may act synergistically. This article aims to provide the latest research findings and theoretical insights to further our understanding of the pathogenesis of MASLD.

Le texte complet de cet article est disponible en PDF.

Keywords : Non-alcoholic fatty liver disease, Apoptosis, Pyroptosis, Autophagy, Ferroptosis, Cuproptosis


Plan


© 2025  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.